
==== Front
Chin Med J (Engl)
Chin Med J (Engl)
CM9
Chinese Medical Journal
0366-6999
2542-5641
Lippincott Williams & Wilkins Hagerstown, MD

CMJ-2023-1558
10.1097/CM9.0000000000003229
00020
3
Correspondence
TGF-β signaling pathway in induced pluripotent stem cells reprogramming
Fan Weiwen 1
Yuan Heling 2
Chang Le 3
Li Qiang 1
Gao Jing 3
Ma Lihua 2
Chen Lvzhe 1
Dai Ying 2
Pan Xinghua 1 2 3
Zhu Xiangqing 1 2 3
Pan Xiangxiang
1 The Basic Medical Laboratory of the 920th Hospital of Joint Logistics Support Force of PLA, Kunming, Yunnan 650032, China
2 The Transfer Medicine Key Laboratory of Cell Therapy Technology of Yunan Province, Kunming, Yunnan 650032, China
3 The Integrated Engineering Laboratory of Cell Biological Medicine of State and Regions, Kunming, Yunnan 650032, China
Correspondence to: Xiangqing Zhu, The Basic Medical Laboratory of the 920th Hospital of Joint Logistics Support Force of PLA, The Transfer Medicine Key Laboratory of Cell Therapy Technology of Yunan Province, The Integrated Engineering Laboratory of Cell Biological Medicine of State and Regions, Kunming, Yunnan 650032, China E-Mail: qing1021zhu@163.com
22 7 2024
20 9 2024
137 18 22632265
14 10 2023
Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

OPEN-ACCESSTRUE
==== Body
pmcTo the Editor: The discovery of the induced pluripotent stem cells (iPSCs) by Takahashi and Yamanaka in 2006 was hailed as a major breakthrough in stem cell research. And a large number of experimental studies have proven that the transforming growth factor-β (TGF-β) signaling pathway is a key signaling pathway in iPSC reprogramming. The TGF-β signaling pathway can promote or inhibit iPSC reprogramming under different conditions [Figure 1]. This article describes the role of the TGF-β signaling pathway in iPSC reprogramming.

Figure 1 The TGF-β signaling pathway can promote or inhibit iPSC reprogramming under different conditions. Akt: Protein kinase B; BMP: Bone morphogenetic protein; Erk: Extracellular signal-regulated kinase; GRB2: Growth factor receptor-bound protein 2; iPSC: Induced pluripotent stem cell; JNK: c-Jun N-terminal Kinase; Klf4: Kruppel-like factor 4; LIMK: Lim-kinase; MEK: Mitogen-activated protein kinase kinase; MEKK1: Mitogen-activated protein kinase kinase kinase 1; MIS: Müllerian inhibiting substance; MKK:MAP kinase kinase; MLC: Myosin light chain; MLK3: Mixed lineage kinase 3; mTOR: Mechanistic target of rapamycin; Oct4: Octamer-binding transcription factor 4; PI3K: Phosphatidylinositol 3-kinase; p38: p38 mitogen-activated protein kinase; Raf: Rapidly accelerated fibrosarcoma; Ras: Rat sarcoma; RhoA: Ras homolog gene family member A; ROCK: Rho-associated protein kinase; ShcA: Src homology 2 domain-containing protein A; SOS: Son of sevenless; Sox2: SRY-box transcription factor 2; S6K: S6 Kinase; TAK1: Transforming growth factor beta-activated kinase 1; TGF-β: Transforming growth factor-β.

According to homology, the TGF-β superfamily can be divided into three large subfamilies: various subtypes of TGF-β (β1, β2, β3), activin, and bone morphogenetic protein (BMP). The TGF-β family transmits signals through receptors, which can be divided into type I receptors (TβRI)/activin receptor-like kinase 5 (ALK5), type II receptors (TβRII), and type III receptors (TβRIII) according to their structural and functional properties. TβRI and TβRII complex is required for TGF-β signal transduction. Upon binding to the ligand, TβRII protein kinase catalyzes the phosphorylation of serine and threonine residues in the guanidine specificity (GS) region of TβRI, resulting in the phosphorylation of a group of downstream signaling protein molecules called Smads in the cell. Smad plus general transcription factor (GTF), other transcription factors, or supplementary protein regulates gene transcription.

In addition, TGF-β/BMP cytokines can also activate non-Smad signaling molecules. For example, activated TβRI induces the formation of the Src homology 2 domain-containing protein A (ShcA)/growth factor receptor-bound protein 2 (GRB2)/son of sevenless (SOS) complex by phosphorylating ShcA and further activates extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) through the Rat sarcoma (Ras)-rapidly accelerated fibrosarcoma (Raf)-Mitogen-activated protein kinase kinase (MEK) pathway; the TGF-β receptor induces TNF receptor associated factor 6 (TRAF6) to catalyze transforming growth factor beta-activated kinase 1 (TAK1) to undergo K63-linked polyubiquitination, which then activates c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) via MAP kinase kinase (MKK). TGF-β can also induce its receptor to bind to p85, the regulatory subunit of phosphoinositide 3-kinase (PI3K), and activate PI3K-protein kinase B (Akt)-mechanistic target of rapamycin (mTOR) signaling for transcriptional regulation. Activated AKT also activates epithelial-mesenchymal transition (EMT) by inhibiting the transcriptional regulation of ribonucleoprotein E1. In addition, TGF-β affects the activity of other EMT-triggering signaling pathways, such as the Notch, Wnt, and integrin signaling pathways. Meanwhile, the TGF-β-induced non-Smad pathway can regulate Smad signaling.

The TGF-β signaling pathway regulates cell differentiation. TGF-β1 has been shown to promote the transformation of human-induced pluripotent stem cells (hiPSCs) -derived neural stem cells (NSCs) into neurons and astrocytes in vitro. The optogenetic modulation of TGF-β signaling can also precisely control the differentiation of hiPSCs into the mesenchymal lineage.[1] It has also been shown that the hydrodynamic stress generated by shaking culture stimulates TGF-β signaling pathway in chondrogenically induced iPSCs (CI-iPSCs), promoting chondrogenic differentiation of mouse iPSCs in vitro.

Inhibition of TGF-β can also regulate the cell differentiation ability. RepSox displaces SRY-box transcription factor 2 (Sox2) by inhibiting the ubiquitously expressed TGF-β signaling pathway in cultures containing stable intermediate cells captured by a partially reprogrammed state. This process, in turn, leads to sustained transcription of Nanog gene, resulting in reprogramming in the absence of Sox2.[2] Moreover, Yamashita et al[3] also found that inhibition of TGF-β could promote the differentiation of human iPSCs into iPSC-derived brain microvascular endothelial-like cells (iBMELCs) and increase the proportion of endothelial cells in differentiated cell population. It was found that inhibition of MEK, DNA methyltransferase (DNMT), and TGF-β was effective in inducing the differentiation of human iPSCs into enterocytes. Human iPSC-derived noncardiomyocyte cardiac cells (hiPSC-NMCCs) differentiate into myofibroblast-like cells when cultured with TGF-β or when transplanted into infarcted mouse hearts.[4] Gong et al[5] achieve directed differentiation of hiPSCs-derived neural crest cells (NCCs) by using chemically defined media containing glycogen synthesis kinase (GSK-3) inhibitors and TGF-β inhibitors.

Indeed, TGF-β signaling has been shown to be essential for maintaining the pluripotency of human pluripotent stem cells (hPSCs). Single-cell RNA sequencing of iPSCs performed by Mabrouk et al[6] revealed that the TGF-β superfamily cytokines have important functions in pluripotency maintenance and cell differentiation during the early embryonic stages. In hPSC, the transcriptional regulator ZNF398 mediates pluripotency and epithelial properties downstream of TGF-β. Mechanistically, ZNF398 binds the active promoter and enhancer to SMAD3 and the histone acetyltransferase EP300, enabling TGF-β target transcription.[7] In the context of somatic reprogramming, inhibition of ZNF398 disrupts pluripotency and epithelial gene activation as well as colony formation.[7] The maintenance of pluripotency in iPSCs cultured in hESF9 medium is absolutely dependent on the presence of TGF-β1.

Activin and Nodal signaling play important roles in maintaining stem cell pluripotency associated with the TGF-β superfamily signaling networks. Upon PI3K activation, EMT/AKT establishes conditions where activin A/SMAD2/3 stimulate self-renewal in hiPSCs by activating target genes, including NANOG. Singh et al[8] found that PI3K/AKT inhibited RAF/MEK/ERK and typical Wnt signaling pathways, allowing SMAD2/3 to activate pluripotency-related target genes such as NANOG in the presence of a high level of PI3K in the undifferentiated state.[8]

TGF-β signaling inhibits mesenchymal-epithelial transition (MET), an important early event in the transformation of fibroblasts into iPSCs. Inhibition of TGF-β signaling provides a possible mechanism to promote the generation of iPSCs. Small molecules targeting the MET machinery, such as the TGF-β receptor (SB431542), MEK (PD0325901), or ROCK (thiazovivin), alone or in combination, significantly increased the reprogramming efficiency. According to current studies, BMP signaling plays an important role in promoting early reprogramming: BMP7 significantly increased the percentage of iPSC reprogramming cell colonies induced by four OSKM genes (OCT4, KLF4, SOX2, and c-Myc) in mouse embryonic fibroblasts (MEFs).[9] Inhibiting TβRI kinase enhanced the efficiency and kinetics of OSKM-reprogrammed MEFs, while activation of the TGF-β pathway prevented reprogramming. Considering TβRI inhibitor treatment is most effective in the early stages of iPSC production, it is believed to exert a synergistic effect with reprogramming factors rather than promoting fibroblast transformation. Besides, it has been evidenced that TβRI inhibitor therapy can replace the solitary effect of C-MYC or SOX2, which suggests that TβRI acts by bypassing the programming factors C-MYC and SOX2 entirely. Ruetz et al[10] showed that constitutive activation of SMAD2/3 increases the efficiency of cell reprogramming in iPSCs thereby serving as a general factor that can enhance transcription factor-mediated reprogramming. Studies have shown that Math6 can counteract TGF-β signaling, affecting the initiating steps of cellular reprogramming, as well as the maintenance of pluripotency and early differentiation.

However, there are still many limitations in the research on the specific mechanism of the TGF-β signaling pathway. For instance, the functions of the TGF-β signaling pathway remain elusive; the regulation of this pathway undergoes dynamic changes in response to different conditions; and there are still unidentified genes involved in its regulation as well as unknown potential for understanding their participation in modulating this pathway.

In conclusion, in the process of exploring the reprogramming mechanism, it was found that the expression of TGF-β signaling pathway changed significantly. However, the specific regulatory mechanisms in the process of reprogramming remain to be further studied.

Funding

This work was supported by grants from the Key Projects in Yunnan Province (No. 202301AY070001-034) and the Project of the Yunnan Provincial Department of Education (No. 2023Y0827).

Conflicts of interest

None.

Weiwen Fan, Heling Yuan, and Le Chang contributed equally to this work.

How to cite this article: Fan WW, Yuan HL, Chang L, Li Q, Gao J, Ma LH, Chen LZ, Dai Y, Pan XH, Zhu XQ. TGF-β signaling pathway in induced pluripotent stem cells reprogramming. Chin Med J 2024;137:2263–2265. doi: 10.1097/CM9.0000000000003229
==== Refs
References

1. Wu JY Yeager K Tavakol DN Morsink M Wang B Soni RK , . Directed differentiation of human iPSCs into mesenchymal lineages by optogenetic control of TGF-β signaling. Cell Rep 2023;42 :112509. doi: 10.1016/j.celrep.2023.112509.37178118
2. Ichida JK Blanchard J Lam K Son EY Chung JE Egli D , . A Small-Molecule Inhibitor of Tgf-β Signaling Replaces Sox2 in Reprogramming by Inducing Nanog. Cell stem cell 2009;5 :491–503.19818703
3. Yamashita M Aoki H Hashita T Iwao T Matsunaga T . Inhibition of transforming growth factor beta signaling pathway promotes differentiation of human induced pluripotent stem cell-derived brain microvascular endothelial-like cells. Fluids Barriers CNS 2020;17 :36. doi: 10.1186/s12987-020-00197-1.32456699
4. Gao L Yang L Wang L Geng Z Wei Y Gourley G , . Relationship Between the Efficacy of Cardiac Cell Therapy and the Inhibition of Differentiation of Human iPSC-Derived Nonmyocyte Cardiac Cells Into Myofibroblast-Like Cells. Circ Res 2018;123 :1313–1325. doi:10.1161/circresaha.118.313094.30566050
5. Gong Y Duan H Wang X Zhao C Li W Dong C , . Transplantation of human induced pluripotent stem cell-derived neural crest cells for corneal endothelial regeneration. Stem Cell Res Ther 2021;12 :214. doi: 10.1186/s13287-021-02267-z.33781330
6. Elsafi Mabrouk MH Goetzke R Abagnale G Yesilyurt B Salz L Cypris O , . The spatial self-organization within pluripotent stem cell colonies is continued in detaching aggregates. Biomaterials 2022;282 :121389. doi: 10.1016/j.biomaterials.2022.121389.35121357
7. Zorzan I Pellegrini M Arboit M Incarnato D Maldotti M Forcato M , . The transcriptional regulator ZNF398 mediates pluripotency and epithelial character downstream of TGF-beta in human PSCs. Nat Commun 2020;11 :2364. doi:10.1038/s41467-020-16205-9.32398665
8. Singh AM Reynolds D Cliff T Ohtsuka S Mattheyses AL Sun Y , . Signaling network crosstalk in human pluripotent cells: A SMAD2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 2012;10 :312–326. doi: 10.1016/j.stem.2012.01.014.22385658
9. Samavarchi-Tehrani P Golipour A David L Sung HK Beyer TA Datti A , . Wrana. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010;7 :64–77. doi: 10.1016/j.stem.2010.04.015.20621051
10. Ruetz T Pfisterer U Di Stefano B Ashmore J Beniazza M Tian TV , . Constitutively Active SMAD2/3 Are Broad-Scope Potentiators of Transcription-Factor-Mediated Cellular Reprogramming. Cell stem cell 2017;21 :791–805.e9. doi:10.1016/j.stem.2017.10.013.29174331
